早期预后良好霍奇金淋巴瘤复发后的疾病特征及常规或大剂量化疗的结局
该研究分析了德国霍奇金研究组HD10和HD13试验中早期预后良好经典型霍奇金淋巴瘤(ES-HL)一线风险 Adapted 治疗后复发的174例患者,比较了复发后接受大剂量化疗联合自体干细胞移植(ASCT)或常规化疗(CTx)的疗效。中位复发时间多超过12个月,以I-II期为主。
要点
- 复发多发生于初诊后12个月以上,且多为I-II期。
- ASCT与常规化疗在第二次PFS上无显著差异。
- BEACOPP是常用的常规化疗方案,可作为部分复发患者的合理选择。
核心结论
- ES-HL现代治疗后复发多发生在初诊12个月后,BEACOPP等联合化疗方案频繁使用,对部分复发患者可能是合理治疗选择。
研究设计与样本
- 对德国霍奇金研究组HD10和HD13试验中ES-HL复发患者进行回顾性分析,共174例(HD10 53例,HD13 121例)。
- 采用Cox比例风险回归比较ASCT与CTx后的第二次PFS,并进行敏感性分析。
主要发现
- 复发大多在初诊后>12个月,以I-II期为主。
- 已知二线治疗的172例中,85例(49%)接受CTx,70例(41%)接受ASCT,11例(6%)仅放疗,4例(2%)姑息单药。
- CTx方案以BEACOPP为主(68%),其次为ABVD(19%)和其他方案(13%)。
关键数值与推荐
- HD13试验≤60岁患者2年第二次PFS率:CTx 94.0%(95%CI 85.7%-100%),ASCT 83.3%(95%CI 71.8%-94.8%)。
临床怎么用
- 对于ES-HL复发患者,尤其是年轻患者,常规化疗(如BEACOPP)可作为ASCT的替代选择之一。
- 年龄>60岁患者预后较差,需个体化治疗决策。
局限性
- 回顾性分析,样本量有限(174例),且包含历史试验HD10,可能存在选择偏倚。
- 部分患者二线治疗信息缺失(2例),且治疗方案异质性较大。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: We evaluated disease and treatment characteristics of patients with relapse after risk-adapted first-line treatment of early-stage, favorable, classic Hodgkin lymphoma (ES-HL). We compared second-line therapy with high-dose chemotherapy and autologous stem cell transplantation (ASCT) or conventional chemotherapy (CTx). METHODS: We analyzed patients with relapse after ES-HL treated within the German Hodgkin Study Group HD10+HD13 trials. We compared, by Cox proportional hazards regression, progression-free survival (PFS) after relapse (second PFS) treated with either ASCT or CTx and performed sensitivity analyses with overall survival (OS) from relapse and Kaplan-Meier statistics. RESULTS: A total of 174 patients' disease relapsed after treatment in the HD10 (n = 53) and HD13 (n = 121) trials. Relapse mostly occurred > 12 months after first diagnosis, predominantly with stage I-II disease. Of 172 patients with known second-line therapy, 85 received CTx (49%); 70, ASCT (41%); 11, radiotherapy only (6%); and 4, palliative single agent therapies (2%). CTx was predominantly bleomycin, etoposide, doxorubicin cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPP [68%]), followed by the combination regimen of doxorubicin, bleomycin, vinblastine, and dacarbazine (19%), or other regimens (13%). Patients aged > 60 years at relapse had shorter second PFS (hazard ratio [HR], 3.0; P = .0029) and were mostly treated with CTx (n = 33 of 49; 67%) and rarely with ASCT (n = 8; 16%). After adjustment for age and a disadvantage of ASCT after the more historic HD10 trial, we did not observe a significant difference in the efficacy of CTx versus ASCT for second PFS (HR, 0.7; 95% CI, 0.3 to 1.6; P = .39). In patients in the HD13 trial who were aged ≤ 60 years, the 2-year, second PFS rate was 94.0% with CTx (95% CI, 85.7% to 100%) versus 83.3% with ASCT (95% CI, 71.8% to 94.8%). Additional sensitivity analyses including OS confirmed these observations. CONCLUSION: After contemporary treatment of ES-HL, relapse mostly occurred > 12 months after first diagnosis. Polychemotherapy regimens such as BEACOPP are frequently administered and may constitute a reasonable treatment option for selected patients with relapse after ES-HL.
引用
- Bröckelmann PJ, Müller H, Guhl T, et al. Relapse After Early-Stage, Favorable Hodgkin Lymphoma: Disease Characteristics and Outcomes With Conventional or High-Dose Chemotherapy. J Clin Oncol. 2020. PMID: 33058716. doi:10.1200/JCO.20.00947
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。